Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of prophylactic pegfilgrastim on day 3 of neoadjuvant DCF chemotherapy in elderly patients with resectable esophageal cancer.
Authors
Go Ikeda
Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan;
Go Ikeda , Yuri Yoshinami , Toru Kadono , Toshiharu Hirose , Akihiro Ohara , Mai Itoyama , Ikuko Azuma , Shun Yamamoto , Yoshitaka Honma , Koshiro Ishiyama , Jyunya Oguma , Hiroyuki Daiko , Ken Kato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 375)
DOI
10.1200/JCO.2023.41.4_suppl.375
Abstract #
375
Poster Bd #
F16
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy of prophylactic pegfilgrastim on day three of preoperative DCF chemotherapy in elderly patients with resectable esophageal cancer.
First Author: Go Ikeda
Poster
2012 Gastrointestinal Cancers Symposium
Preliminary result of a multicenter phase II study of chemoradiotherapy with docetaxel for elderly patients with stage II/III esophageal carcinoma.
First Author: Jun Hashimoto
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.
First Author: Mikako Tamba
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma.
First Author: Vikas S. Ostwal